These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
366 related items for PubMed ID: 20547037
1. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Docherty JP, Baker RA, Eudicone J, Mathew S, Marcus RN, McQuade RD, Mankoski R. Schizophr Res; 2010 Jul; 120(1-3):199-203. PubMed ID: 20547037 [Abstract] [Full Text] [Related]
2. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115 [Abstract] [Full Text] [Related]
3. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S. J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981 [Abstract] [Full Text] [Related]
4. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data. Robb AS, Carson WH, Nyilas M, Ali M, Forbes RA, Iwamoto T, Assunção-Talbott S, Whitehead R, Pikalov A. J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794 [Abstract] [Full Text] [Related]
5. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Kane JM, Crandall DT, Marcus RN, Eudicone J, Pikalov A, Carson WH, Swyzen W. Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313 [Abstract] [Full Text] [Related]
12. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, Iwamoto T. Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381 [Abstract] [Full Text] [Related]
15. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Andrezina R, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, McQuade RD. Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982 [Abstract] [Full Text] [Related]
19. Trial of aripiprazole in the treatment of first-episode schizophrenia. Lee HY, Ham BJ, Kang RH, Paik JW, Hahn SW, Lee MS, Lee MS. Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024 [Abstract] [Full Text] [Related]
20. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. Volavka J, Czobor P, Citrome L, McQuade RD, Carson WH, Kostic D, Hardy S, Marcus R. J Clin Psychiatry; 2005 Nov; 66(11):1362-6. PubMed ID: 16420071 [Abstract] [Full Text] [Related] Page: [Next] [New Search]